Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2181308 in advanced hepatocellular carcinoma
NCT00415155Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Primary completion
- Jan 2011
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of gataparsen in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Planned start Aug 2008; status: withdrawn.
02
Drugs
gataparsen
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00415155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415155.